Erlotinib Completed Phase 2 Trials for Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00392665Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck